Hideki Onishi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hideki Onishi has a total of 212 co-authors. Here are the top co-authors by number of shared publications:
- Mayumi Ishida
Departments of Psycho-Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
30 shared publications Mayumi Ishida
Department of Psycho‐Oncology Saitama Medical University International Medical Center Hidaka Japan
20 shared publicationsAkira Yoshioka
Mitsubishi Kyoto Hospital
18 shared publicationsIzumi Sato
Nagasaki University
18 shared publications- Nozomu Uchida
Department of Supportive Care Medicine, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
18 shared publications Nozomu Uchida
Saitama Medical University International Medical Center
14 shared publications
Latest Publications
- Open Access
- 20 July 2026
- Published by Cambridge University Press (CUP) in Palliative and Supportive Care
- Vol. 24, e200
Thiamine deficiency observed in family caregivers of AYA cancer patients
Objective: Although it is known that parents caring for adolescent and young adult (AYA) cancer patients experience physical and psychological stress, to our knowledge, there are no reports regarding thiamine deficiency (TD) in this population. Method: From a series of cancer patient caregivers, we identified TD in a mother caring for an AYA cancer patient and report our experience with this case, as treatment enabled the prevention of Wernicke encephalopathy (WE). Results: A 49-year-old woman who had been caring for her 18-year-old son after he developed graft-versus-host disease following bone marrow transplantation for leukemia visited our psycho-oncology department at the recommendation of her son’s attending physician after witnessing her son experience a seizure. Thirteen months after the initial consultation, she developed difficulty climbing stairs, suggesting a possible physical abnormality. Blood tests revealed a markedly decreased hemoglobin level of 5.7 g/dL, and subsequent evaluation led to a diagnosis of iron deficiency anemia. Five days later, her thiamine level was found to be markedly reduced at 19 ng/mL (reference range: 24–66 ng/mL), and oral thiamine at a dose of 75 mg was initiated. No progression to WE, such as disturbance of consciousness, was observed. Significance of the results: Parents caring for AYA cancer patients are profoundly affected both physically and psychologically by their child’s condition. In the future, attention should be paid to the nutritional status (including TD) of families caring for AYA cancer patients, as this may contribute to improving quality of life for both patients and their families.
- 20 July 2026
- Published by Cambridge University Press (CUP) in Palliative and Supportive Care
- Vol. 24, e200
Open AccessThiamine deficiency observed in family caregivers of AYA cancer patients
Objective: Although it is known that parents caring for adolescent and young adult (AYA) cancer patients experience physical and psychological stress, to our knowledge, there are no reports regarding thiamine deficiency (TD) in this population. Method: From a series of cancer patient caregivers, we identified TD in a mother caring for an AYA cancer patient and report our experience with this case, as treatment enabled the prevention of Wernicke encephalopathy (WE). Results: A 49-year-old woman who had been caring for her 18-year-old son after he developed graft-versus-host disease following bone marrow transplantation for leukemia visited our psycho-oncology department at the recommendation of her son’s attending physician after witnessing her son experience a seizure. Thirteen months after the initial consultation, she developed difficulty climbing stairs, suggesting a possible physical abnormality. Blood tests revealed a markedly decreased hemoglobin level of 5.7 g/dL, and subsequent evaluation led to a diagnosis of iron deficiency anemia. Five days later, her thiamine level was found to be markedly reduced at 19 ng/mL (reference range: 24–66 ng/mL), and oral thiamine at a dose of 75 mg was initiated. No progression to WE, such as disturbance of consciousness, was observed. Significance of the results: Parents caring for AYA cancer patients are profoundly affected both physically and psychologically by their child’s condition. In the future, attention should be paid to the nutritional status (including TD) of families caring for AYA cancer patients, as this may contribute to improving quality of life for both patients and their families.
- Open Access
- 10 July 2026
- Published by BMJ in BMJ Supportive & Palliative Care
Testimony and judicial decisions that disregard medical evidence regarding delirium can lead to significant suffering for defendants
- 10 July 2026
- Published by BMJ in BMJ Supportive & Palliative Care
Open AccessTestimony and judicial decisions that disregard medical evidence regarding delirium can lead to significant suffering for defendants
- Open Access
- 14 May 2026
- Published by Cambridge University Press (CUP) in Palliative and Supportive Care
- Vol. 24, e141
A case of recurrent breast cancer with severe hepatic dysfunction: Integrating narrative-based medicine and clinical decision-making
Background: Patients with recurrent breast cancer and liver metastases complicated by hepatic failure have limited treatment options and poor prognoses. Narrative-based medicine (NBM) and shared decision-making (SDM) may support patient-centered decisions even in critical clinical situations Objectives: To describe the role of NBM and SDM in guiding treatment decisions for a patient with recurrent breast cancer and diffuse hepatic metastases associated with severe liver dysfunction. Methods: We present the case of a woman with recurrent breast cancer who developed hepatic failure caused by diffuse liver metastases. Repeated SDM discussions were conducted among the patient, her family, and a board-certified breast oncologist with certification in palliative care. Chemotherapy with eribulin was initiated together with intensive supportive care despite life-threatening organ failure. Conclusion: Following the initial onset of adverse effects, the patient’s liver function improved, allowing continuation of outpatient chemotherapy and fulfillment of her goal of spending meaningful time with family. The patient survived for approximately 5 months after treatment initiation. Significance of results: This case suggests that individualized care guided by NBM and SDM may support safe and goal-concordant treatment decisions, even near the end of life. Integration of oncologic and palliative expertise may help align medical interventions with patient values and preferences in complex clinical situations.
- 14 May 2026
- Published by Cambridge University Press (CUP) in Palliative and Supportive Care
- Vol. 24, e141
Open AccessA case of recurrent breast cancer with severe hepatic dysfunction: Integrating narrative-based medicine and clinical decision-making
Background: Patients with recurrent breast cancer and liver metastases complicated by hepatic failure have limited treatment options and poor prognoses. Narrative-based medicine (NBM) and shared decision-making (SDM) may support patient-centered decisions even in critical clinical situations Objectives: To describe the role of NBM and SDM in guiding treatment decisions for a patient with recurrent breast cancer and diffuse hepatic metastases associated with severe liver dysfunction. Methods: We present the case of a woman with recurrent breast cancer who developed hepatic failure caused by diffuse liver metastases. Repeated SDM discussions were conducted among the patient, her family, and a board-certified breast oncologist with certification in palliative care. Chemotherapy with eribulin was initiated together with intensive supportive care despite life-threatening organ failure. Conclusion: Following the initial onset of adverse effects, the patient’s liver function improved, allowing continuation of outpatient chemotherapy and fulfillment of her goal of spending meaningful time with family. The patient survived for approximately 5 months after treatment initiation. Significance of results: This case suggests that individualized care guided by NBM and SDM may support safe and goal-concordant treatment decisions, even near the end of life. Integration of oncologic and palliative expertise may help align medical interventions with patient values and preferences in complex clinical situations.
- Open Access
- 11 May 2026
- Published by BMJ in BMJ Supportive & Palliative Care
- Vol. 16 (6) , 1484-1488
Thiamine deficiency in outpatients at a regional cancer centre in Japan: cross-sectional observational study
Objective To examine the prevalence of thiamine deficiency and its potential risk factors in cancer outpatients. Methods A cross-sectional study of cancer outpatients aged ≥20 years at a regional hospital in Kyoto, Japan (January–February 2022). Thiamine deficiency was defined as ≤23 ng/mL by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Multivariable logistic regression was used to estimate ORs and 95% CIs for potential risk factors for thiamine deficiency. Results A total of 106 patients were included in this study (mean age 68.3 years, 61% female). Of the 106 patients, 27 (25.5%) had low thiamine levels despite the absence of recognised deficiency symptoms. In multivariable logistic regression analysis, the adjusted OR was 4.05 (95% CI 0.88 to 18.60). Conclusions The prevalence of thiamine deficiency was 25.5% among cancer outpatients without recognised symptoms. An association between low dietary intake and thiamine deficiency was suggested, though further large-scale studies are needed to confirm risk factors and guide management strategies.
- 11 May 2026
- Published by BMJ in BMJ Supportive & Palliative Care
- Vol. 16 (6) , 1484-1488
Open AccessThiamine deficiency in outpatients at a regional cancer centre in Japan: cross-sectional observational study
Objective To examine the prevalence of thiamine deficiency and its potential risk factors in cancer outpatients. Methods A cross-sectional study of cancer outpatients aged ≥20 years at a regional hospital in Kyoto, Japan (January–February 2022). Thiamine deficiency was defined as ≤23 ng/mL by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Multivariable logistic regression was used to estimate ORs and 95% CIs for potential risk factors for thiamine deficiency. Results A total of 106 patients were included in this study (mean age 68.3 years, 61% female). Of the 106 patients, 27 (25.5%) had low thiamine levels despite the absence of recognised deficiency symptoms. In multivariable logistic regression analysis, the adjusted OR was 4.05 (95% CI 0.88 to 18.60). Conclusions The prevalence of thiamine deficiency was 25.5% among cancer outpatients without recognised symptoms. An association between low dietary intake and thiamine deficiency was suggested, though further large-scale studies are needed to confirm risk factors and guide management strategies.
- Open Access
- 17 April 2026
- Published by BMJ in BMJ Supportive & Palliative Care
Thiamine deficiency in cancer patients at initial admission to a palliative care unit: a single-centre cross-sectional study
Objectives: Thiamine deficiency (TD) has been increasingly reported among patients undergoing active cancer treatment. However, its status in end-of-life cancer patients admitted to palliative care units remains unclear. This study aimed to determine the prevalence of TD and associated factors in end-of-life cancer patients on initial admission to a palliative care unit. Methods: This single-centre descriptive cross-sectional study included end-of-life cancer patients admitted for the first time to a palliative care unit between 1 January 2020 and 31 December 2023. Whole blood thiamine concentrations measured on admission were analysed using high-performance liquid chromatography. The TD group was defined as <24.0 ng/mL and the thiamine normal group as 24.0–66.0 ng/mL. Patient characteristics were summarised using descriptive statistics, and factors associated with TD were examined using multivariable logistic regression, adjusting for age and clinical background variables. Results: TD was identified in 85 (36%) of 234 patients. Multivariable logistic regression showed that only a serum albumin level <3.0 g/dL was significantly associated with TD (adjusted OR 2.05, 95% CI 1.10 to 3.90; p=0.023). Age, body mass index, Eastern Cooperative Oncology Group performance status, a history of chemotherapy within 1 month prior to admission and gastrointestinal malignancy were not significantly associated with TD. Conclusion: TD was identified in 36% of end-of-life cancer patients and found to be associated with serum albumin level. In end-of-life cancer patients, particularly those with low serum albumin levels, clinicians should be mindful of the possibility of TD.
- 17 April 2026
- Published by BMJ in BMJ Supportive & Palliative Care
Open AccessThiamine deficiency in cancer patients at initial admission to a palliative care unit: a single-centre cross-sectional study
Objectives: Thiamine deficiency (TD) has been increasingly reported among patients undergoing active cancer treatment. However, its status in end-of-life cancer patients admitted to palliative care units remains unclear. This study aimed to determine the prevalence of TD and associated factors in end-of-life cancer patients on initial admission to a palliative care unit. Methods: This single-centre descriptive cross-sectional study included end-of-life cancer patients admitted for the first time to a palliative care unit between 1 January 2020 and 31 December 2023. Whole blood thiamine concentrations measured on admission were analysed using high-performance liquid chromatography. The TD group was defined as <24.0 ng/mL and the thiamine normal group as 24.0–66.0 ng/mL. Patient characteristics were summarised using descriptive statistics, and factors associated with TD were examined using multivariable logistic regression, adjusting for age and clinical background variables. Results: TD was identified in 85 (36%) of 234 patients. Multivariable logistic regression showed that only a serum albumin level <3.0 g/dL was significantly associated with TD (adjusted OR 2.05, 95% CI 1.10 to 3.90; p=0.023). Age, body mass index, Eastern Cooperative Oncology Group performance status, a history of chemotherapy within 1 month prior to admission and gastrointestinal malignancy were not significantly associated with TD. Conclusion: TD was identified in 36% of end-of-life cancer patients and found to be associated with serum albumin level. In end-of-life cancer patients, particularly those with low serum albumin levels, clinicians should be mindful of the possibility of TD.
- Open Access
- 3 April 2026
- Published by Wiley in Journal of General and Family Medicine
- Vol. 27 (3) , e70114
Characteristics of Patients Diagnosed With Cancer After Emergency Medical Center Transport in Japan
Background: Although early cancer detection relies on routine primary care and screening, some patients first receive a cancer diagnosis after emergency transport. We described patients diagnosed with (or strongly suspected of having) cancer after emergency transport to a tertiary Emergency and Acute Medicine Center in Japan, focusing on access to primary care and family support. Methods: We conducted a retrospective cross‐sectional study of patients transported between April 2007 and December 2023 who were diagnosed with or strongly suspected of cancer at the initial visit. We extracted age, sex, cancer site, presenting symptoms, presence of an established primary care medical institution, and cohabiting family members. Results: Among 76,989 patients who visited the Center during the study period, 202 (0.6%) were diagnosed with (or strongly suspected of having) cancer. Mean age was 73.1 years (range 22–101), and 141 (69.8%) were male. The most common cancer sites were colorectal/rectal ( n = 49), gastric ( n = 46), lung ( n = 29), and liver ( n = 21). Presentations commonly involved bleeding, pain, dyspnea, or general deterioration. Overall, 142 patients (70.3%) had an established primary care medical institution, and 152 (75.2%) lived with family members. Conclusions: Many patients with emergency‐based cancer diagnoses had documented access to primary care and cohabiting family members. These descriptive findings underscore the need for future comparative studies to clarify diagnostic pathways and factors associated with emergency‐based cancer diagnosis.
- 3 April 2026
- Published by Wiley in Journal of General and Family Medicine
- Vol. 27 (3) , e70114
Open AccessCharacteristics of Patients Diagnosed With Cancer After Emergency Medical Center Transport in Japan
Background: Although early cancer detection relies on routine primary care and screening, some patients first receive a cancer diagnosis after emergency transport. We described patients diagnosed with (or strongly suspected of having) cancer after emergency transport to a tertiary Emergency and Acute Medicine Center in Japan, focusing on access to primary care and family support. Methods: We conducted a retrospective cross‐sectional study of patients transported between April 2007 and December 2023 who were diagnosed with or strongly suspected of cancer at the initial visit. We extracted age, sex, cancer site, presenting symptoms, presence of an established primary care medical institution, and cohabiting family members. Results: Among 76,989 patients who visited the Center during the study period, 202 (0.6%) were diagnosed with (or strongly suspected of having) cancer. Mean age was 73.1 years (range 22–101), and 141 (69.8%) were male. The most common cancer sites were colorectal/rectal ( n = 49), gastric ( n = 46), lung ( n = 29), and liver ( n = 21). Presentations commonly involved bleeding, pain, dyspnea, or general deterioration. Overall, 142 patients (70.3%) had an established primary care medical institution, and 152 (75.2%) lived with family members. Conclusions: Many patients with emergency‐based cancer diagnoses had documented access to primary care and cohabiting family members. These descriptive findings underscore the need for future comparative studies to clarify diagnostic pathways and factors associated with emergency‐based cancer diagnosis.
- Open Access
- 2 February 2026
- Published by Cambridge University Press (CUP) in Palliative and Supportive Care
- Vol. 24, e50
Suicide attempt by a cancer caregiver: A husband who attempted suicide two months after his wife was diagnosed with advanced stomach cancer
Objectives: The families of cancer patients experience many forms of distress, as a result of their loved one’s cancer diagnosis. However, there have been no reports of suicide attempts of caregivers directly linked to the diagnosis of advanced cancer in a family member. Methods: We reported a caregiver who attempt suicide two months after his wife was diagnosed with advanced cancer. Results: The subject was a 69-year-old male who had been caring for his wife, diagnosed with advanced stomach cancer, for two months. The patient’s husband, acting as her caregiver, was referred by his wife (a cancer patient) to meet with a nurse. He reported insomnia and a desire for hastened death. Despite repeated recommendations for specialized care at a caregiver clinic, he declined. Following an argument with his wife at home, he felt unable to cope and attempted suicide. The husband had no psychiatric history but had a history of colon cancer. After the attempt suicide, he began visiting the “Caregivers’ Clinic,” where he received ongoing psychological support that continued until the death of his wife. Significance of results: In cancer care, it is essential to continuously assess not only the patient’s suicide risk, but also that of closely related family members.
- 2 February 2026
- Published by Cambridge University Press (CUP) in Palliative and Supportive Care
- Vol. 24, e50
Open AccessSuicide attempt by a cancer caregiver: A husband who attempted suicide two months after his wife was diagnosed with advanced stomach cancer
Objectives: The families of cancer patients experience many forms of distress, as a result of their loved one’s cancer diagnosis. However, there have been no reports of suicide attempts of caregivers directly linked to the diagnosis of advanced cancer in a family member. Methods: We reported a caregiver who attempt suicide two months after his wife was diagnosed with advanced cancer. Results: The subject was a 69-year-old male who had been caring for his wife, diagnosed with advanced stomach cancer, for two months. The patient’s husband, acting as her caregiver, was referred by his wife (a cancer patient) to meet with a nurse. He reported insomnia and a desire for hastened death. Despite repeated recommendations for specialized care at a caregiver clinic, he declined. Following an argument with his wife at home, he felt unable to cope and attempted suicide. The husband had no psychiatric history but had a history of colon cancer. After the attempt suicide, he began visiting the “Caregivers’ Clinic,” where he received ongoing psychological support that continued until the death of his wife. Significance of results: In cancer care, it is essential to continuously assess not only the patient’s suicide risk, but also that of closely related family members.
- Open Access
- 28 July 2025
- Published by Wiley in Journal of General and Family Medicine
- Vol. 26 (6) , 626-629
Wernicke encephalopathy observed in a cancer patient receiving terminal‐stage home care
We report an 80 year old man in the terminal stage of cancer receiving home care. On the 18th day after starting home care, he experienced a sudden onset of impaired consciousness, unsteadiness of gait, and ophthalmoplegia. Based on the clinical symptoms and a prolonged loss of appetite, Wernicke encephalopathy (WE) was suspected. Thiamine 100 mg was administered intravenously, and 20 minutes later, the patient responded to verbal stimuli. After 1 h, he was able to engage in conversation. When impaired consciousness occurs in cancer patients receiving home care, it is important to consider WE as a differential diagnosis.
- 28 July 2025
- Published by Wiley in Journal of General and Family Medicine
- Vol. 26 (6) , 626-629
Open AccessWernicke encephalopathy observed in a cancer patient receiving terminal‐stage home care
We report an 80 year old man in the terminal stage of cancer receiving home care. On the 18th day after starting home care, he experienced a sudden onset of impaired consciousness, unsteadiness of gait, and ophthalmoplegia. Based on the clinical symptoms and a prolonged loss of appetite, Wernicke encephalopathy (WE) was suspected. Thiamine 100 mg was administered intravenously, and 20 minutes later, the patient responded to verbal stimuli. After 1 h, he was able to engage in conversation. When impaired consciousness occurs in cancer patients receiving home care, it is important to consider WE as a differential diagnosis.
- 22 April 2025
- Published by Elsevier in General Hospital Psychiatry
- Vol. 95, 62
Diagnostic yield of laboratory testing in hospitalized older adults with altered mental status
- 22 April 2025
- Published by Elsevier in General Hospital Psychiatry
- Vol. 95, 62
Diagnostic yield of laboratory testing in hospitalized older adults with altered mental status
- Open Access
- 13 March 2025
- Published by Cambridge University Press (CUP) in Palliative and Supportive Care
- Vol. 23, e64
Opioid withdrawal syndrome induced by naldemedine administration in a cancer patient without brain metastasis
Objectives: Naldemedine is a peripherally acting μ-opioid receptor antagonist used to treat opioid-induced constipation. As this drug does not cross the blood–brain barrier, it is believed that patients without brain metastases do not experience opioid withdrawal symptoms. Methods: Here, we experienced a case in which a cancer patient without brain metastasis presented with anxiety and restlessness that was severe enough to interfere with daily life. The patient was diagnosed with naldemedine-induced opioid withdrawal syndrome. Results: The patient was a 66-year-old male with liver cancer metastasizing to the chest wall, but without brain metastasis. Oxycodone was started at 10 mg/day 2 months prior to his visit to our department to treat pain related to the chest wall metastasis, and was increased to 100 mg/day 1 month later and maintained at that dose. Naldemedine was administered as a countermeasure against opioid-induced constipation. The patient developed anxiety and restlessness 10 days prior to his initial visit to our department. After detailed examination, naldemedine-related opiod withdrawal syndrome was suspected on the basis of anxiety, agitation, and episodes of sudden onset sweating, and these symptoms disappeared within 2 days after the discontinuation of naldemedine, with no recurrence observed thereafter. In addition, head MRI revealed no brain metastasis. Significance of the results: Even in patients without brain metastasis, naldemedine can induce opioid withdrawal symptoms, so caution is required with patients receiving this drug. In addition, when psychiatric symptoms are pronounced, as in this case, withdrawal symptoms may be underdiagnosed.
- 13 March 2025
- Published by Cambridge University Press (CUP) in Palliative and Supportive Care
- Vol. 23, e64
Open AccessOpioid withdrawal syndrome induced by naldemedine administration in a cancer patient without brain metastasis
Objectives: Naldemedine is a peripherally acting μ-opioid receptor antagonist used to treat opioid-induced constipation. As this drug does not cross the blood–brain barrier, it is believed that patients without brain metastases do not experience opioid withdrawal symptoms. Methods: Here, we experienced a case in which a cancer patient without brain metastasis presented with anxiety and restlessness that was severe enough to interfere with daily life. The patient was diagnosed with naldemedine-induced opioid withdrawal syndrome. Results: The patient was a 66-year-old male with liver cancer metastasizing to the chest wall, but without brain metastasis. Oxycodone was started at 10 mg/day 2 months prior to his visit to our department to treat pain related to the chest wall metastasis, and was increased to 100 mg/day 1 month later and maintained at that dose. Naldemedine was administered as a countermeasure against opioid-induced constipation. The patient developed anxiety and restlessness 10 days prior to his initial visit to our department. After detailed examination, naldemedine-related opiod withdrawal syndrome was suspected on the basis of anxiety, agitation, and episodes of sudden onset sweating, and these symptoms disappeared within 2 days after the discontinuation of naldemedine, with no recurrence observed thereafter. In addition, head MRI revealed no brain metastasis. Significance of the results: Even in patients without brain metastasis, naldemedine can induce opioid withdrawal symptoms, so caution is required with patients receiving this drug. In addition, when psychiatric symptoms are pronounced, as in this case, withdrawal symptoms may be underdiagnosed.